Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Akoya Biosciences Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Akoya Biosciences (NASDAQ:AKYA) reported Q4 sales of $16.16 million. Earnings fell to a loss of $17.67 million, resulting in a 52.13% decrease from last quarter. Akoya Biosciences collected $13.48 million in revenue during Q3, but reported earnings showed a $11.62 million loss.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.